Immunohistochemistry Doctors Abroad — Page 3

Dr. Kodchanut Litleaungdej is a hematologist at Intrarat Hospital in Bangkok. She specializes in the treatment of leukemia, myeloma, and complex lymphomas. Dr. Litleaungdej co-authored a clinical risk prediction model for cancer-associated venous thromboembolism. She graduated with second-class honors from Naresuan University before completing a hematology fellowship at Thammasat University.

• Performs bone marrow transplantation and CAR T-cell therapy.
• Treats blood disorders including aplastic anemia and thrombocytopenia.
• Provides chemotherapy and biological therapy for hematologic malignancies.
• Works at ISO-certified Intrarat Hospital, which treats 100,000 patients annually.

Dr. Hasan Mutlu is a medical oncologist at Medical Park Antalya Hospital Complex. He specializes in immunotherapy, targeted cancer therapies, and genetic research in cancer treatment. Dr. Mutlu received his medical degree from Hacettepe University. He holds the title of Professor of Medicine. Dr. Mutlu focuses on organ tumor diagnosis and chemotherapy.

• Specializes in both medical and pediatric oncology cases.
• Treats complex conditions including neuroblastoma, Wilms tumor, and Ewing's sarcoma.
• Performs biological therapies and stays active in next-generation genetic research.
• Works at the Mediterranean region’s largest private hospital with PET-CT and LINAC technology.

Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.

• Treats a wide range of cancers including breast, lung, and prostate.
• Expert in hematology-oncology for conditions like leukemia, myeloma, and lymphoma.
• Performs systemic therapies such as chemotherapy, immunotherapy, and targeted biological therapy.
• Works at a facility that houses specialized oncology-bone marrow units and LINAC technology.

Dr. Ercan Ozden is a medical oncologist and internal medicine specialist at VM Medical Park Pendik. He provides treatment for a wide range of cancers, including breast, lung, and colon cancer. Dr. Ozden trained at Istanbul University, Cerrahpasa Faculty of Medicine. He later completed a medical oncology subspecialty at Kocaeli University.

• Specializes in immunotherapy, target therapy, and chemotherapy for complex cases.
• Treats patients at a JCI-accredited hospital in Istanbul.
• Performs staging and biopsies for liver, lung, and pancreatic tumors.
• Provides targeted immunotherapy using medications like Keytruda.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at Liv Hospital Topkapı. He specializes in treating colon, breast, gastric, and lung cancers. He previously served as the Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital. Dr. Atci is a member of the American Society of Clinical Oncology (ASCO).

• Author of 19 peer-reviewed papers on gastrointestinal, thoracic, and endocrine cancers.
• Published studies on survival outcomes for stage IIB colon cancer in the Journal of Chemotherapy.
• Researches prognostic biomarkers using PET/CT scans and metabolic tumor volume.
• Treats complex oncological cases at the university-affiliated İstinye University clinic.

Dr. Irfan Cicin is a Professor of Medical Oncology at İstinye University Liv Hospital Topkapı. He specializes in treating complex cancers, including glioblastoma, lung cancer, and pancreatic tumors. He serves as a professor at the Trakya University Faculty of Medicine. Dr. Cicin previously served as a physician in the Turkish Air Force.

• Performs systemic therapies such as immunotherapy, chemotherapy, and hormone therapy.
• Treats a wide range of conditions including gynecologic, orthopedic, and neuro-oncology cases.
• Expert in HIPEC and chemoembolization for liver and abdominal malignancies.
• Works at a 300-bed university hospital with 33 medical departments.

Dr. Nail Paksoy is an associate professor of medical oncology at Medipol Bahçelievler Hospital. He is board-certified by the European Society for Medical Oncology (ESMO). Dr. Paksoy specializes in lung, breast, and gastrointestinal cancers. He uses modern immunotherapy and targeted therapy protocols. His clinic is JCI-accredited for high safety standards.

• Served as a subinvestigator in over 8 international clinical trials for Roche and Pfizer.
• Authored over 40 research articles in journals indexed by SCI and SSCI.
• Completed dual fellowships in allergy-immunology and medical oncology.
• Treats complex sarcomas and renal cell carcinomas with systemic therapies.

Dr. Gal Goldstein leads the Department of Pediatric Oncology at Hadassah Hospital. He uses immunohistochemistry to identify specific antigens and tailor cancer treatments for children.

• Forbes listed him among the best doctors in Israel
• Heads the pediatric oncology and hemato-oncology division at Hadassah Hospital
• Specializes in precision medicine for solid tumors and complex blood disorders
• Member of SIOP – an international group setting pediatric oncology standards
• Earned his medical degree from the prestigious Tel Aviv University

Professor Beni Boursi is a high-level oncology specialist at Sheba Medical Center. He uses immunohistochemistry to identify specific cancer proteins for targeted treatment planning.

• Completed subspecialty training in oncology at the University of Pennsylvania
• Trained at MD Anderson and Mayo Clinic in the United States
• Works in the Gastrointestinal Cancer Department at Israel's largest hospital
• Published research in Science and other top-tier medical journals
• Member of the American Society for Cancer Research

Professor Francesc Graus is a pioneer who established the first diagnostic criteria for paraneoplastic syndromes. He identified essential antibodies used globally in immunohistochemistry for neurological dysfunction.

• Founder and past president of the European Association of Neuro-Oncology
• Completed a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York
• Serves as the coordinator of the neuroimmunology program at IDIBAPS in Barcelona
• Awarded Doctor Honoris Causa by Lyon University for his work in neuroimmunology
• Leads the expert group that defined international standards for rare immune-related disorders

Dr. Jair Bar is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He specializes in treating advanced non-small cell lung cancer using personalized immunotherapy and targeted treatments. Dr. Bar holds a PhD in Molecular Biology and leads a research lab focused on immunotherapy resistance.

• Chair of the Israel Lung Cancer Group.
• Board-certified in both Medical Oncology and Radiotherapy Oncology.
• Treats patients at Sheba Medical Center, a top-10 globally ranked hospital.
• Uses molecular and genetic profiling to create precise cancer treatment plans.

Dr. Abraham Avigdor is the Director of the Institute of Hematology at Sheba Medical Center. He is a global authority on lymphoma, CAR-T therapy, and complex blood cancers. Dr. Avigdor founded the Israeli Lymphoma Working Group. He helps lead a clinic ranked 7th worldwide by Newsweek in 2026.

• Authored over 130 scientific publications on hemato-oncology and cellular therapy.
• Pioneered the integration of CAR-T cell therapy for lymphoma and myeloma.
• Leads allogeneic and autologous bone marrow transplantation programs.
• Served as the Chairman of the Israeli Lymphoma Study Group.

Dr. Avichai Shimoni is the Director of Bone Marrow Transplantation at Sheba Medical Center. He treats complex blood cancers. He completed a specialized fellowship at the MD Anderson Cancer Center. Dr. Shimoni uses allogeneic and autologous transplants for high-risk patients. He is a professor and Chairman of Hematology at Tel Aviv University.

• Named among Israel’s Best Doctors by Forbes for 2025 and 2026.
• Authored over 250 scientific papers on cellular therapies and transplantation.
• Provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma.
• Works at Sheba Medical Center, a top-10 hospital globally per Newsweek.

Dr. Hila Magen is a leading Israeli hemato-oncologist at Sheba Medical Center. She heads the Multiple Myeloma and Amyloidosis Unit. Dr. Magen specializes in treating complex plasma cell disorders and high-risk myeloma. She is a principal investigator for innovative point-of-care CAR-T therapy programs. Her work brings advanced immunotherapies into routine clinical care.

• Authored over 100 scientific publications and landmark myeloma studies.
• Completed fellowships at MD Anderson and University of Arkansas for Medical Sciences.
• Performs CAR-T cell therapy and bone marrow transplantations.
• Works at Sheba Medical Center, ranked 7th worldwide in 2026 by Newsweek.